There are mixed opinions on the stock, with 2 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for CTNM is 14.20M and currently, short sellers hold a 7.88% ratio of that float. The average trading volume of CTNM on November 20, 2024 was 73.45K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
CTNM) stock’s latest price update
Contineum Therapeutics Inc (NASDAQ: CTNM)’s stock price has gone decline by -15.98 in comparison to its previous close of 15.83, however, the company has experienced a -32.26% decrease in its stock price over the last five trading days. businesswire.com reported 2024-11-18 that SAN DIEGO–(BUSINESS WIRE)–Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments in the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced authorization of its Investigational New Drug (IND) application from the U.S. Food and Drug Administr.
CTNM’s Market Performance
Contineum Therapeutics Inc (CTNM) has seen a -32.26% fall in stock performance for the week, with a -17.24% decline in the past month and a -28.11% plunge in the past quarter. The volatility ratio for the week is 10.63%, and the volatility levels for the past 30 days are at 5.79% for CTNM. The simple moving average for the last 20 days is -22.57% for CTNM’s stock, with a simple moving average of -24.22% for the last 200 days.
Analysts’ Opinion of CTNM
Many brokerage firms have already submitted their reports for CTNM stocks, with Robert W. Baird repeating the rating for CTNM by listing it as a “Outperform.” The predicted price for CTNM in the upcoming period, according to Robert W. Baird is $32 based on the research report published on October 22, 2024 of the current year 2024.
Stifel, on the other hand, stated in their research note that they expect to see CTNM reach a price target of $29. The rating they have provided for CTNM stocks is “Buy” according to the report published on April 30th, 2024.
RBC Capital Mkts gave a rating of “Outperform” to CTNM, setting the target price at $30 in the report published on April 30th of the current year.
CTNM Trading at -24.16% from the 50-Day Moving Average
After a stumble in the market that brought CTNM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -39.55% of loss for the given period.
Volatility was left at 5.79%, however, over the last 30 days, the volatility rate increased by 10.63%, as shares sank -18.30% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -26.19% lower at present.
During the last 5 trading sessions, CTNM fell by -32.26%, in comparison to the 20-day moving average, which settled at $17.18. In addition, Contineum Therapeutics Inc saw -13.64% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CTNM starting from DANIEL LORRAIN, who proposed sale 26,370 shares at the price of $17.21 back on Nov 18 ’24. After this action, DANIEL LORRAIN now owns shares of Contineum Therapeutics Inc, valued at $453,828 using the latest closing price.
Stock Fundamentals for CTNM
The total capital return value is set at -0.21.
Based on Contineum Therapeutics Inc (CTNM), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -54.58.
Currently, EBITDA for the company is 23.57 million with net debt to EBITDA at 1.06. The liquidity ratio also appears to be rather interesting for investors as it stands at 37.06.
Conclusion
In conclusion, Contineum Therapeutics Inc (CTNM) has seen bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
